BR112022005173A2 - Imunocitocina compreendendo complexo de proteína heterodimérica baseado em il-15/il-15ra, ácidos nucleicos, vetor, método célula hospedeira, composições e usos associados - Google Patents
Imunocitocina compreendendo complexo de proteína heterodimérica baseado em il-15/il-15ra, ácidos nucleicos, vetor, método célula hospedeira, composições e usos associadosInfo
- Publication number
- BR112022005173A2 BR112022005173A2 BR112022005173A BR112022005173A BR112022005173A2 BR 112022005173 A2 BR112022005173 A2 BR 112022005173A2 BR 112022005173 A BR112022005173 A BR 112022005173A BR 112022005173 A BR112022005173 A BR 112022005173A BR 112022005173 A2 BR112022005173 A2 BR 112022005173A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein complex
- heterodimeric protein
- vector
- compositions
- nucleic acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
IMUNOCITOCINA COMPREENDENDO COMPLEXO DE PROTEÍNA HETERODIMÉRICA BASEADO EM IL-15/IL-15R?, ÁCIDOS NUCLEICOS, VETOR, MÉTODO CÉLULA HOSPEDEIRA, COMPOSIÇÕES E USOS ASSOCIADOS. A presente invenção refere-se a uma imunocitocina compreendendo um complexo proteico heterodimérico baseado em IL-15/IL-15Ra, e à sua utilização como agente terapêutico, em particular como agente para o tratamento de câncer e uma doença autoimune. A presente invenção refere-se ainda a uma imunocitocina compreendendo um complexo proteico heterodimérico baseado em uma IL-15/IL-15Ra e um anticorpo imunomodulador, e ao seu uso como agente terapêutico, em particular como agente para o tratamento de câncer e uma doença autoimune.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019129569A RU2753282C2 (ru) | 2019-09-19 | 2019-09-19 | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
PCT/RU2020/050233 WO2021054867A1 (ru) | 2019-09-19 | 2020-09-20 | Иммуноцитокин, включающий гетеро димерный белковый комплекс на основе il-15 и il-15rα |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005173A2 true BR112022005173A2 (pt) | 2022-08-16 |
Family
ID=74873995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005173A BR112022005173A2 (pt) | 2019-09-19 | 2020-09-20 | Imunocitocina compreendendo complexo de proteína heterodimérica baseado em il-15/il-15ra, ácidos nucleicos, vetor, método célula hospedeira, composições e usos associados |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230011234A1 (pt) |
EP (1) | EP4032539A4 (pt) |
JP (1) | JP2022549276A (pt) |
KR (1) | KR20220145323A (pt) |
CN (1) | CN115297885A (pt) |
AR (1) | AR120011A1 (pt) |
AU (1) | AU2020351560A1 (pt) |
BR (1) | BR112022005173A2 (pt) |
CA (1) | CA3151780A1 (pt) |
CO (1) | CO2022003156A2 (pt) |
JO (1) | JOP20220071A1 (pt) |
MA (1) | MA56286B1 (pt) |
MX (1) | MX2022003306A (pt) |
PE (1) | PE20220603A1 (pt) |
RU (1) | RU2753282C2 (pt) |
TW (1) | TW202124420A (pt) |
UY (1) | UY38889A (pt) |
WO (1) | WO2021054867A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202102777PA (en) | 2018-09-27 | 2021-04-29 | Xilio Development Inc | Masked cytokine polypeptides |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
CN116854821A (zh) * | 2022-08-15 | 2023-10-10 | 海徕科(北京)生物技术有限公司 | IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
KR102070098B1 (ko) * | 2010-09-21 | 2020-01-28 | 알토 바이오사이언스 코포레이션 | 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법 |
EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
MX2016001555A (es) | 2013-08-08 | 2016-08-03 | Cytune Pharma | Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra). |
EP3093295B1 (en) * | 2014-01-08 | 2020-05-27 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-15 heterogeneous dimer protein and uses thereof |
KR102398246B1 (ko) * | 2014-06-30 | 2022-05-17 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
JP6709456B2 (ja) | 2014-12-19 | 2020-06-17 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | インターロイキン15タンパク複合体およびそれらの用途 |
RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
AU2017342560B2 (en) * | 2016-10-14 | 2022-03-17 | Xencor, Inc. | IL15/IL15Ralpha heterodimeric Fc-fusion proteins |
MX2019004681A (es) * | 2016-10-21 | 2019-10-07 | Altor Bioscience Corp | Moleculas basadas en il-15 multimericas. |
US11129883B2 (en) * | 2017-03-06 | 2021-09-28 | Altor BioScience, LLC. | IL-15-based fusions to IL-12 and IL-18 |
RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
JP2020529832A (ja) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質 |
WO2019010222A2 (en) * | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | POLYNUCLEOTIDES ENCODING IMMUNOSTIMULATING FUSION MOLECULES AND USES THEREOF |
-
2019
- 2019-09-19 RU RU2019129569A patent/RU2753282C2/ru active
-
2020
- 2020-09-18 AR ARP200102607A patent/AR120011A1/es unknown
- 2020-09-20 JO JOP/2022/0071A patent/JOP20220071A1/ar unknown
- 2020-09-20 PE PE2022000447A patent/PE20220603A1/es unknown
- 2020-09-20 US US17/761,838 patent/US20230011234A1/en active Pending
- 2020-09-20 AU AU2020351560A patent/AU2020351560A1/en active Pending
- 2020-09-20 JP JP2022518285A patent/JP2022549276A/ja active Pending
- 2020-09-20 MX MX2022003306A patent/MX2022003306A/es unknown
- 2020-09-20 BR BR112022005173A patent/BR112022005173A2/pt unknown
- 2020-09-20 CN CN202080080165.8A patent/CN115297885A/zh active Pending
- 2020-09-20 WO PCT/RU2020/050233 patent/WO2021054867A1/ru active Application Filing
- 2020-09-20 EP EP20865705.6A patent/EP4032539A4/en active Pending
- 2020-09-20 MA MA56286A patent/MA56286B1/fr unknown
- 2020-09-20 KR KR1020227013100A patent/KR20220145323A/ko unknown
- 2020-09-20 CA CA3151780A patent/CA3151780A1/en active Pending
- 2020-09-21 TW TW109132634A patent/TW202124420A/zh unknown
- 2020-09-22 UY UY0001038889A patent/UY38889A/es unknown
-
2022
- 2022-03-18 CO CONC2022/0003156A patent/CO2022003156A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022003306A (es) | 2022-04-26 |
TW202124420A (zh) | 2021-07-01 |
CO2022003156A2 (es) | 2022-04-19 |
KR20220145323A (ko) | 2022-10-28 |
JP2022549276A (ja) | 2022-11-24 |
RU2019129569A3 (pt) | 2021-03-19 |
CA3151780A1 (en) | 2021-03-25 |
AR120011A1 (es) | 2022-01-26 |
MA56286A1 (fr) | 2023-05-31 |
PE20220603A1 (es) | 2022-04-25 |
EP4032539A1 (en) | 2022-07-27 |
CN115297885A (zh) | 2022-11-04 |
MA56286B1 (fr) | 2023-09-27 |
US20230011234A1 (en) | 2023-01-12 |
AU2020351560A1 (en) | 2022-11-24 |
RU2019129569A (ru) | 2021-03-19 |
EP4032539A4 (en) | 2023-09-13 |
RU2753282C2 (ru) | 2021-08-12 |
UY38889A (es) | 2021-04-30 |
JOP20220071A1 (ar) | 2023-01-30 |
WO2021054867A1 (ru) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022005173A2 (pt) | Imunocitocina compreendendo complexo de proteína heterodimérica baseado em il-15/il-15ra, ácidos nucleicos, vetor, método célula hospedeira, composições e usos associados | |
PH12019502621A1 (en) | Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer | |
BR112018076281A2 (pt) | imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo | |
CO2020001823A2 (es) | Conjugados de citoquina para el tratamiento de enfermedades autoinmunes | |
CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
BR112016028066A2 (pt) | composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira | |
BR112018006531A2 (pt) | proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit | |
BR112016014293A2 (pt) | região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune | |
BR112018014028A2 (pt) | anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico | |
EA201891656A1 (ru) | Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний | |
BR112021022666A2 (pt) | Frações de separação e seus métodos e uso | |
CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
BR112021019471A2 (pt) | Composições imunoterapêuticas e uso das mesmas | |
BR112018009437A2 (pt) | controle de níveis de oxirredução celular | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
AR099289A1 (es) | Proteínas de fusión de interleucina-2 y usos de las mismas | |
BR112022027028A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso | |
BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
BR112022010179A2 (pt) | Anticorpos anti-vírus da febre amarela, e métodos de sua geração e uso | |
BR112022022922A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso | |
BR112022004972A2 (pt) | Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso | |
AR104484A1 (es) | Anticuerpos anti-psma como agentes terapéuticos |